0000905718-14-000492.txt : 20140804 0000905718-14-000492.hdr.sgml : 20140804 20140804074937 ACCESSION NUMBER: 0000905718-14-000492 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140804 DATE AS OF CHANGE: 20140804 EFFECTIVENESS DATE: 20140804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scilex Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001603542 IRS NUMBER: 800861274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-214267 FILM NUMBER: 141011494 BUSINESS ADDRESS: STREET 1: 101 LINDENWOOD DR. STREET 2: SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 949-413-2672 MAIL ADDRESS: STREET 1: 101 LINDENWOOD DR. STREET 2: SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: Scilex Pharmaceuticals, Inc DATE OF NAME CHANGE: 20140325 D/A 1 primary_doc.xml X0707 D/A LIVE 0001603542 Scilex Pharmaceuticals Inc. 101 LINDENWOOD DR. SUITE 225 MALVERN PA PENNSYLVANIA 19355 949-413-2672 DELAWARE None Scilex Pharmaceuticals, Inc Corporation true 2012 William Pedranti 101 Lindenwood Drive Suite 225 Malvern PA PENNSYLVANIA 19355 Executive Officer Director Anthony P. Mack 101 Lindenwood Drive Suite 225 Malvern PA PENNSYLVANIA 19355 Executive Officer Director Eric Floyd 101 Lindenwood Drive Suite 225 Malvern PA PENNSYLVANIA 19355 Director Jerrold B. Sendrow 101 Lindenwood Drive Suite 225 Malvern PA PENNSYLVANIA 19355 Director Richard Cohen 101 Lindenwood Drive Suite 225 Malvern PA PENNSYLVANIA 19355 Executive Officer Pharmaceuticals Decline to Disclose 06b true 0001144204-14-017812 2014-03-20 false true false 100 NONE None Aegis Capital Corp. 15007 810 7TH AVENUE 18TH FLOOR NEW YORK NY NEW YORK 10019 AZ ARIZONA CA CALIFORNIA CT CONNECTICUT IA IOWA NY NEW YORK false NONE None Henri Ji None 6099 RANCHO DIEGUENO PO BOX 3531 RANCHO SANTA CA CALIFORNIA 92067 PA PENNSYLVANIA false NONE None George Uy None 1632 CONTESSA IRVINE CA CALIFORNIA 92620 PA PENNSYLVANIA false 5250000 5001700 248300 false 12 434000 true 0 Aegis was also issued warrants to purchase up to 352,543 shares. Two advisors were issued an aggregate of 3,380,608 shares in consideration of advisor's introduction of potential funding sources. 0 false Scilex Pharmaceuticals Inc. /s/ Anthony Mack Anthony Mack Chief Executive Officer and President 2014-08-04